

Russell D Petty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8165122/publications.pdf>

Version: 2024-02-01

41
papers

1,794
citations

516710

16
h-index

315739

38
g-index

44
all docs

44
docs citations

44
times ranked

3025
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor- <i>Amplified</i> Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	1.6	9
2	Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2091-2111.	4.1	18
3	Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the GO2 trial. <i>Journal of Geriatric Oncology</i> , 2022, 13, 287-293.	1.0	8
4	Identification of coronavirus particles by electron microscopy: a complementary tool for deciphering COVID-19. <i>European Respiratory Journal</i> , 2022, , 2200754.	6.7	1
5	Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 361-377.	2.3	2
6	The impact of COVID-19 on systemic anticancer treatment delivery in Scotland. <i>British Journal of Cancer</i> , 2021, 124, 1353-1356.	6.4	22
7	Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 3126-3140.	7.0	11
8	Real-world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review). <i>International Journal of Oncology</i> , 2021, 58, .	3.3	7
9	Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer. <i>JAMA Oncology</i> , 2021, 7, 869.	7.1	83
10	Cancer Treatment Helpline: a retrospective study of the NHS Tayside experience. <i>BMJ Open Quality</i> , 2021, 10, e001488.	1.1	1
11	Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers. <i>British Journal of Cancer</i> , 2021, 125, 1068-1079.	6.4	23
12	Best supportive care and prognosis: advanced gastroesophageal adenocarcinoma. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2020-002637.	1.6	6
13	Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the young international society of geriatric oncology. <i>Journal of Geriatric Oncology</i> , 2021, , .	1.0	0
14	Cardiotoxicity and Chemotherapy- <i>The Role of Precision Medicine</i> . <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 90.	2.5	3
15	A modified Delphi process to establish future research priorities in malignant oesophagogastric surgery. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2020, 18, 321-326.	1.8	9
16	Novel biomarkers for risk stratification of Barrett's oesophagus associated neoplastic progression- <i>epithelial HMGB1 expression and stromal lymphocytic phenotype</i> . <i>British Journal of Cancer</i> , 2020, 122, 545-554.	6.4	14
17	Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1585-1587.	6.4	2
18	Why is renal impairment associated with poorer cancer specific survival in breast cancer patients?: a comparison with patients with other comorbidities. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1786-1792.	2.2	3

#	ARTICLE	IF	CITATIONS
19	Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. , 2019, 203, 107395.		76
20	Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 854-862.	8.1	47
21	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 420-435.	10.7	191
22	A Deep Learning Framework for Predicting Response to Therapy in Cancer. Cell Reports, 2019, 29, 3367-3373.e4.	6.4	137
23	Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.. Journal of Clinical Oncology, 2019, 37, 4006-4006.	1.6	49
24	Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma. Lancet, The, 2018, 392, 97-98.	13.7	5
25	Prognostic RNAs in oesophageal squamous cell carcinoma: small is beautiful. Gut, 2017, 66, 210-211.	12.1	1
26	Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. Journal of Clinical Oncology, 2017, 35, 2279-2287.	1.6	100
27	Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial). Cancer Chemotherapy and Pharmacology, 2016, 77, 819-827.	2.3	14
28	Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phosphate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer, 2015, 15, 762.	2.6	38
29	Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma. Molecular Cytogenetics, 2015, 8, 78.	0.9	8
30	Biomarkers and novel agents in esophago-gastric cancer: are we making progress?. Expert Review of Anticancer Therapy, 2015, 15, 1103-1119.	2.4	6
31	Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncology, The, 2014, 15, 894-904.	10.7	270
32	Serpin B3 Is Associated with Poor Survival after Chemotherapy and Is a Potential Novel Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1502-1509.	1.1	9
33	Exclusive rights in gastric cancer genomics: Figure 1. Gut, 2012, 61, 638-640.	12.1	4
34	Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nature Genetics, 2012, 44, 1131-1136.	21.4	162
35	Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose. Journal of Gastrointestinal Cancer, 2012, 43, 168-176.	1.3	21
36	Predicting Response to Treatment in Gastroesophageal Junction Adenocarcinomas: Combining Clinical, Imaging, and Molecular Biomarkers. Oncologist, 2010, 15, 270-284.	3.7	22

#	ARTICLE	IF	CITATIONS
37	Tumor Transcriptome Reveals the Predictive and Prognostic Impact of Lysosomal Protease Inhibitors in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 1729-1744.	1.6	61
38	Gene Expression Profiling in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 3237-3248.	7.0	131
39	Novel Fluoropyrimidines: Improving the Efficacy and Tolerability of Cytotoxic Therapy. <i>Current Cancer Drug Targets</i> , 2004, 4, 191-204.	1.6	8
40	Bone metastasis from epithelial ovarian carcinoma. <i>Lancet Oncology</i> , The, 2002, 3, 513.	10.7	8
41	Comparison of MTT and ATP-based assays for the measurement of viable cell number. <i>Luminescence</i> , 1995, 10, 29-34.	0.0	201